Association Between CGM Metrics in Type 2 Diabetes Pregnancy and Perinatal Morbidity

Launched by CENTRE HOSPITALIER SUD FRANCILIEN · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how continuous glucose monitoring (CGM) can help understand the health of babies born to mothers with type 2 diabetes during pregnancy. Researchers want to see if the timing of starting CGM and how well blood sugar levels are controlled can affect complications that might arise for the baby at birth. Essentially, they are studying whether better management of blood sugar can lead to healthier outcomes for both mothers and their babies.

To participate in this study, women must be adults diagnosed with type 2 diabetes, either before or during pregnancy, and have used continuous glucose monitoring at least once while pregnant. Unfortunately, women with multiple pregnancies, those who have ended their pregnancy early, or who deliver outside of the specified healthcare facility will not be eligible. This trial is not yet recruiting participants, but once it begins, women who meet the criteria can help contribute valuable information that could improve care for future pregnancies in women with type 2 diabetes.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Adult patient
• • Patient diagnosed with type 2 diabetes before or during pregnancy (fasting blood glucose \> 126 mg/dL, blood glucose \> 200 mg/dL after an oral glucose tolerance test, or HbA1c \> 6.5%)
• • Patient who has undergone continuous glucose monitoring at least once during pregnancy
• Exclusion Criteria:
• • Multiple pregnancy
• • Pregnancy terminated before 20 weeks of amenorrhea
• • Delivery outside CHSF
• • Patient and/or legal guardians of the newborn who objected to the use of data